Patents Examined by Maria G Leavitt
-
Patent number: 11583556Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: GrantFiled: August 26, 2020Date of Patent: February 21, 2023Assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Branden Moriarity, Beau Webber, Modassir Choudhry, R. Scott McIvor, David Largaespada, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Patent number: 11576982Abstract: The present invention relates to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glycoproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatment of cancer or CNS disorders.Type: GrantFiled: August 31, 2018Date of Patent: February 14, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Benhur Lee, Karina Palomares, Olivier Pernet
-
Patent number: 11572554Abstract: The present invention relates to a method of obtaining an enriched population of a target polynucleotide using a synthetic single guide RNA (sgRNA) for an sgRNA-guided nucleic acid-binding protein, as well as to a method of obtaining a pool of target-irrelevant synthetic single guide RNAs (sgRNAs) for a sgRNA-guided nucleic acid-binding protein. Also provided is a target polynucleotide and sgRNAs obtainable by the methods of the invention. Further envisaged is a kit comprising a pool of sgRNAs obtainable by the method of the invention, and the use of a pool of sgRNAs obtainable by the methods of the invention.Type: GrantFiled: October 29, 2019Date of Patent: February 7, 2023Assignee: Siemens Healthcare GmbHInventors: Yiwei Huang, Maximilian Würstle, Tivadar Mach, Stefan Prause
-
Patent number: 11564381Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.Type: GrantFiled: September 1, 2020Date of Patent: January 31, 2023Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.Inventors: Yuelei Shen, Jiawei Yao, Chaoshe Guo, Yanan Guo, Yang Bai, Rui Huang, Lei Zhao, Meiling Zhang
-
Patent number: 11559560Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.Type: GrantFiled: September 12, 2018Date of Patent: January 24, 2023Assignee: PHICO THERAPEUTICS LTD.Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
-
Patent number: 11525119Abstract: Embodiments disclosed here are production methods and compositions of engineered immune cells, such as B or T lymphocytes, from limited lineage myeloid progenitor cells, or from pluripotent stem cells, or from multilineage hematopoietic progenitor cells comprising the addition of various cell differentiation transcription factors and inhibiting epigenetic histone methylations in said cells.Type: GrantFiled: September 6, 2017Date of Patent: December 13, 2022Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Linda Thuy Vo, George Q. Daley
-
Patent number: 11518982Abstract: A method for producing a mesenchymal cell line derived from a vertebrate adipose tissue, and a mesenchymal cell line derived from a vertebrate adipose tissue produced by the method. Advantageously, a method for producing a mesenchymal cell line derived from a vertebrate adipose tissue is achieved more simply, in a shorter period of time, and more efficiently. Also, a mesenchymal cell line is derived from a vertebrate adipose tissue produced by the production method. The method for producing a mesenchymal cell line derived from a vertebrate adipose tissue comprises: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell of a vertebrate adipose tissue into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate adipose tissue.Type: GrantFiled: November 30, 2016Date of Patent: December 6, 2022Assignee: AdipoSeeds, Inc.Inventors: Yumiko Matsubara, Yasuo Ikeda, Keiichi Tozawa, Hideyuki Saya, Hiroyuki Nobusue
-
Patent number: 11510998Abstract: The present invention provides a synthetic MMACHC polynucleotide comprising a polynucleotide encoding MMACHC that is codon-optimized for expression in a human. Also provided is a polypeptide encoded by a synthetic MMACHC polynucleotide, an expression vector comprising a MMACHC gene sequence under the control of a chicken beta actin (CBA) promoter, and an expression vector comprising a synthetic MMACHC polynucleotide. Methods of treating cobalamin C deficiency and for detecting or tracking exogenous MMACHC are also provided.Type: GrantFiled: April 27, 2016Date of Patent: November 29, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Charles P. Venditti, Jennifer L. Sloan
-
Patent number: 11497774Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: GrantFiled: April 4, 2022Date of Patent: November 15, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Patent number: 11498973Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.Type: GrantFiled: September 16, 2021Date of Patent: November 15, 2022Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITEDInventors: Yutian Wei, Lin Zhu, Yanfeng Li, Yihong Yao, Xin Yao, Jiaqi Huang, Li Zhang, Shigui Zhu, Xiaoteng Lv
-
Patent number: 11471509Abstract: The present disclosure describes the fusogenic activity of the Myomaker protein. This polypeptide, when expressed in non-muscle cells, is able to drive fusion of the cell with a muscle cell, but not with other non-muscle cells. The use of this protein and cell expressing it in the delivery of exogenous genetic material to muscle cells also is described.Type: GrantFiled: April 9, 2019Date of Patent: October 18, 2022Assignee: The Board of Regents of The University of Texas SystemInventors: Eric Olson, Douglas P. Millay
-
Patent number: 11464801Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.Type: GrantFiled: September 30, 2019Date of Patent: October 11, 2022Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 11453719Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.Type: GrantFiled: September 30, 2019Date of Patent: September 27, 2022Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 11446396Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.Type: GrantFiled: September 19, 2018Date of Patent: September 20, 2022Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
-
Patent number: 11440950Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.Type: GrantFiled: July 16, 2021Date of Patent: September 13, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Matthew Franklin
-
Patent number: 11441195Abstract: This disclosure describes the characteristics of the “energetic” cancer stem cell (e-CSC) phenotype. This distinct sub-population of cancer stem cells (CSCs) has a unique energetic profile compared to bulk CSCs, being more glycolytic, having higher mitochondrial mass and elevated oxidative metabolism. e-CSCs also show an increased capacity to undergo cell cycle progression, enhanced anchorage-independent growth, and ALDH-positivity. The e-CSC phenotype presents new targets for cancer therapeutics, and in particular the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis of e-CSCs makes them highly susceptible to mitochondrial inhibitors that target e-CSC anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Gene products for e-CSCs are disclosed, as well as classes of mitochondrial inhibiting therapeutic agents. Also disclosed are methods for identifying and separating e-CSCs from bulk cell populations.Type: GrantFiled: June 19, 2019Date of Patent: September 13, 2022Assignee: LUNELLA BIOTECH, INC.Inventors: Michael P. Lisanti, Federica Sotgia, Marco Fiorillo
-
Patent number: 11440958Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.Type: GrantFiled: November 22, 2017Date of Patent: September 13, 2022Assignee: NATIONAL UNIVERSITY OF SINGAPOREInventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
-
Patent number: 11421008Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.Type: GrantFiled: September 6, 2019Date of Patent: August 23, 2022Assignee: University of MassachusettsInventors: Jack L. Leonard, Deborah M. Leonard, Karl J. Simin
-
Patent number: 11414478Abstract: The present invention provides cells, transgenic animals, including transgenic mammals and particularly rodents comprising engineered immunoglobulin (Ig) alleles. Such engineered alleles, wherein an Ig light chain CL exon [C? or C? (C?1, C?2 or C?3)] is incorporated into the Ig heavy chain locus, are capable of producing heavy chain-only antibodies as a single chain VH antibody (scVHAb) or heavy chain antibody (HCAb) comprising two extended scVHAbs. The scVHAb comprises an antigen-binding part consisting of a VH domain and the immunoglobulin constant domains CL, which is either C? or C?, and CH1, in the order from N-terminus to C-terminus: VH-L1-CL-L2-CH1, wherein L1 and L2 are each, independently, peptidic linkers; and wherein CL is paired with CH1 through beta-sheet contact thereby obtaining a CL/CH1 dimer.Type: GrantFiled: July 20, 2018Date of Patent: August 16, 2022Assignee: TRIANNI, INC.Inventors: Werner Mueller, Matthias Wabl
-
Patent number: 11406667Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.Type: GrantFiled: August 4, 2021Date of Patent: August 9, 2022Assignees: Triumvira Immunologies USA, Inc., McMaster UniversityInventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi